CHECKIT
23.11.2021 13:02:09 CET | Business Wire | Press release
Checkit’s intelligent operations platform will be rolled out to 441 bp forecourts in Australia and New Zealand following a new agreement with the multinational energy company.
Checkit has agreed a four-year partnership with bp Australia Pty Limited and bp Oil New Zealand Limited, following the successful completion of a pilot programme.
Checkit’s platform replaces paper-based processes with digital assistants in the form of a mobile app which prompts, guides and captures the activity of store assistants, and provides managers with real-time oversight. The platform also encompasses automated monitoring via fridge-mounted sensors and handheld temperature probes to enhance food safety, reduce waste and save time spent on manual checking routines.
The Checkit platform has already been effectively deployed at more than 320 bp-owned forecourts in the UK for more than 18 months. The rollout in Australia and New Zealand is the latest phase of Checkit’s expanding international partnership with bp.
Hannah Barnes, Vice President of Operational Excellence for Europe and Southern Africa at bp, said: “The Checkit platform has already delivered significant value across our UK retail operations by eradicating paperwork, saving staff time, reducing waste and providing data that enables us to optimise the availability of food at our Wild Bean Cafes. All of this contributes to better experiences for both our customers and our frontline teams. Checkit has been central to our intelligent store operations programme and its introduction to Australia and New Zealand is a natural evolution of that.”
Kit Kyte, CEO of Checkit, said: “The introduction of our platform into bp sites across Australia and New Zealand is a further affirmation of the importance of this technology in enabling intelligent operations across deskless workforces. The value can be seen in greater efficiency, improved staff engagement and retention, stock optimisation, production scheduling, waste reduction and many other measurable parameters. We have worked closely with bp to make this happen and look forward to continuing this valuable partnership.”
About Checkit
Checkit is the intelligent operations platform for deskless workforces, enabling operational agility and intelligent decision-making in large multinational and complex national organisations. The solution offers optional plugins for sensor networks and smart building management.
The Checkit Connect platform prompts, guides, captures and analyses frontline activities through digital workflows. Real-time data is captured from multiple workplaces. The platform empowers leaders to comprehend and continually improve processes, enhancing innovation, productivity, efficiency, energy usage, waste reduction, customer experience, safety and compliance.
Checkit provides intelligent operations tools to the retail, franchise, healthcare, life sciences, facilities management, catering, manufacturing, hospitality and commercial property sectors.
Checkit has customers including the NHS, bp, Waitrose, Sodexo and Center Parcs. The Checkit platform generates around 11bn data points per year from sensors and digital workflows.
Checkit is headquartered in Cambridge, UK, with its operations centre in Fleet, UK, and US office in Florida. The company has over 170 employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005136/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom